Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response

Patients with metastatic HER2 breast cancer (MBC) often become resistant to HER 2 targeted therapy and have recurrence of disease. The Panacea trial suggested that HER2 MBC patients were more likely to respond to checkpoint therapy if TIL were present or if tumor expressed PD-L1. We assessed whether...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Immunol
Egile Nagusiak: Kodumudi, Krithika N., Ramamoorthi, Ganesan, Snyder, Colin, Basu, Amrita, Jia, Yongsheng, Awshah, Sabrina, Beyer, Amber P., Wiener, Doris, Lam, Lian, Zhang, Hongtao, Greene, Mark I., Costa, Ricardo L. B., Czerniecki, Brian J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2019
Gaiak:
Immunology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6702967/
https://ncbi.nlm.nih.gov/pubmed/31475002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.01939
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak